SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2026
Parenteral treprostinil in paediatric pulmonary arterial hypertension: a systematic review and meta-analysis.
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPaediatric pulmonary arterial hypertension (PAH) shares commonalities with adult disease but is essentially different regarding complexity and is usually more challenging to treat. Current treatment recommendations are based on expert opinion, small-scale paediatric studies and knowledge and consolidated guidelines for adults. Parenteral prostacyclins are recommended for high-risk patients but evidence is limited to cohort studies and retrospective data evaluations. The aim of this article was to summarise the available evidence on the efficacy and safety of parenteral treprostinil for paediatric PAH through a systematic review and to evaluate selected efficacy end-points through meta-analysis.
methodA systematic literature search (January 2000-April 2024) was conducted in PubMed, Google Scholar and clinical trial registries. Eligible studies included those reporting long-term outcomes of parenteral treprostinil in children with PAH. Moreover, a meta-analysis of selected efficacy end-points was performed based on published results from studies meeting predefined criteria.
results32 studies encompassing 766 paediatric PAH patients treated with parenteral prostacyclins were identified; 649 patients received treprostinil. The meta-analysis was based on five publications including a total of 143 treprostinil-naïve patients. Despite the lack of randomised controlled trials, available data clearly indicate a treatment benefit of parenteral treprostinil in paediatric PAH. Literature data are supported by statistically significant results in the meta-analysis for PAH-relevant efficacy end-points.
conclusionBased on currently available published data, parenteral treprostinil is effective and safe in the treatment of paediatric PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.